Published · Aurelis Peptides
SS-31 and elamipretide refer to the same peptide in the published literature. MTP-131 is another development name you may encounter. A search for “SS-31 vs elamipretide” is therefore usually a naming question, rather than a comparison between two different peptide sequences.
That connection helps you find the right papers. When reviewing a quotation, go one step further: match the name to the complete offered specification. Aurelis lists SS-31 25 mg per unit. An alias does not add a second catalogue product or establish the contents of a particular batch.
SS-31, elamipretide and MTP-131 at a glance
| Name | Where it appears | What to keep clear |
|---|---|---|
| SS-31 | Laboratory papers and the Aurelis catalogue | Aurelis lists 25 mg content per unit |
| Elamipretide | Published clinical research and medicine information | Identify the specific preparation being discussed |
| MTP-131 | Development and study records | Match the study or document to its full title |
| Forzinity | A specific FDA-approved elamipretide medicine | A distinct finished product, not the Aurelis listing |
How do the papers connect these names?
The introduction to the original Barth-syndrome trial paper identifies SS-31 as elamipretide. The paper also uses MTP-131 in its trial description. This provides a direct link between the names within a published study. Read Thompson and colleagues, 2021.
A separate 2018 trial calls its study MMPOWER, expanding that abbreviation with the name MTP-131, while its title and abstract refer to elamipretide. Keeping both names in a literature search can bring these records together. Read the original MMPOWER report. The study identifier and publication date help you distinguish one investigation from another.
Why does SS-31 appear in mitochondrial research?
SS-31 is a four-amino-acid peptide studied for its interaction with cardiolipin, a lipid in the inner mitochondrial membrane. In a 2014 laboratory study, researchers examined cardiolipin-containing membrane models and mitochondrial preparations. They observed effects on electron transfer and the efficiency of ATP production under those conditions. ATP is an energy-carrying molecule used by cells. Read Birk and colleagues, 2014.
Those experiments explain the mitochondrial focus of the name. For a wider comparison with a different molecule, use our MOTS-C vs SS-31 guide. MOTS-C is a separate peptide; it is not another alias for elamipretide.
What does the SS-31 25 mg listing mean?
The 25 mg figure is listed content per unit. It is not a liquid volume, concentration, treatment amount or measure of how a preparation will perform. Keep the amount attached to the SS-31 catalogue entry when you prepare an enquiry.
Ask how that content is defined in the offered specification and supporting report. If a record adds a salt or counterion description, request a clear explanation of the reporting basis. Do not calculate an assumed adjustment or transfer a value from a different preparation. The counterion guide and content vs concentration guide explain those separate fields.
What should match across the documents?
Start with the full name and agreed molecular identity, including any sequence or chemical-form details the project requires. Then match the product reference, lot number, reported content, method, report date and issuer. A document using elamipretide should explain its connection to an SS-31 quotation rather than leaving you to assume it.
For example, an SS-31 quotation and an MTP-131 report may use linked names, but that alone does not establish that the report concerns the offered lot. Request the written name mapping and traceable lot reference together. Our quality-documentation page provides the broader review questions.
How does Forzinity fit into the naming?
FDA granted accelerated approval to the specific medicine Forzinity, containing elamipretide, on 19 September 2025 for patients with Barth syndrome weighing at least 30 kg. That is product-specific information. Read FDA’s approval announcement.
The Aurelis 25 mg catalogue material is not that approved medicine. Recognising the common peptide name does not make different finished preparations interchangeable or transfer an approval to an Aurelis item. FDA’s trial snapshot identifies the clinical population and preparation behind its report.
Turn the name check into a clear enquiry
Send “SS-31 / elamipretide”, the listed 25 mg content, your required quantity and preferred presentation. Both vials and pen-style kits remain part of the Aurelis collection; request the actual configuration and supporting records for the selected item. A peptide alias does not define a liquid fill, kit contents or storage specification.
Add your destination in Australia, Canada or the USA and ask the team to confirm local availability. If your project cites a particular paper or uses MTP-131 in its records, include that reference so the reply can address the same identity and specification.
Send an SS-31 specification enquiry or email sales@aurelispeptides.com.
Primary research and official sources
- Thompson et al., Genetics in Medicine, 2021 — linked names in an original clinical report.
- Karaa et al., Neurology, 2018 — elamipretide and MTP-131 in the MMPOWER study.
- Birk et al., British Journal of Pharmacology, 2014 — SS-31 membrane and mitochondrial experiments.
- FDA, Forzinity accelerated approval announcement, 2025 and original-approval trial snapshot — the specific medicine and study population.